Breaking News

The firm said that UHC will cover the test for patients with major depressive disorder or anxiety who have failed to respond to one or more treatments.

The firm's molecular diagnostics revenue increased nearly 11 percent with global sales of $170.9 million.

The firm's flow cytometry business contributed about $13.2 million, or 16 percent of the firm's consolidated revenue in the second quarter.

The assays will combine genomic and gene expression analyses to better understand driver mutations in prostate, breast, and pancreatic cancers.

The partners will request samples from more than 2,500 existing and new participants in the foundation's Preeclampsia Registry for sequencing analysis.

The new company, whose name was not disclosed, will provide preclinical and clinical immune monitoring and biomarker services to biopharma companies.

Blue Cross Blue Shield of Michigan's members will able to access Interpace's tests on an in-network basis, which will limit their out-of-pocket expenses.

Qiagen's Q2 revenues of $381.6 million represented 5 percent year-over-year growth at constant exchange rates, but came in just under the Wall Street estimate.

An international team documented TP53 mutation-related genomic changes across dozens of cancer types using data generated with five platforms for the Cancer Genome Atlas project.

The company's Q2 revenues were up less than 1 percent from $596.2 million in Q2 2018, and short of the average Wall Street estimate of $601.4 million.

Much of the growth was driven by contributions from Genoptix, which NeoGenomics acquired in late 2018. Organically, revenues were up 20 percent.

The partners will use the GeoMx Digital Spatial Profiler to identify new biomarkers in high-risk breast cancer and the nCounter to evaluate leukemia fusion testing.